Managing Constipation in Patients with Depression

Antidepressant Options

The American College of Physicians guidelines state that all second-generation antidepressants have similar efficacy for treating depression, but differ in their side effect profiles, particularly regarding gastrointestinal effects 1
Bupropion has the lowest risk of constipation among antidepressants and is effective for depression with minimal anticholinergic effects 1
SSRIs, such as sertraline, citalopram, and fluoxetine, are generally less likely to cause constipation than TCAs and have lower constipation risk 1
SNRIs, such as duloxetine, have a moderate risk of constipation and may be effective for depression with comorbid pain conditions 2
The British Society of Gastroenterology warns against the use of TCAs when constipation is a major concern due to their significant anticholinergic effects 4

Secondary amine TCAs, such as nortriptyline and desipramine, have fewer anticholinergic effects than tertiary amines and may be beneficial at low doses 3
SSRIs may be preferable as they can accelerate small bowel transit, and bupropion remains the safest option regarding constipation 4
Low-dose TCAs may actually be beneficial, and secondary amine TCAs are preferred over tertiary amines 3
Starting with lower doses of SSRIs, such as sertraline 25 mg daily, is recommended 5

Increasing fluid intake and physical activity can help manage constipation 1
Consider adding a stimulant laxative, such as senna, or peripherally acting μ-opioid receptor antagonists for opioid-induced constipation 7
Switching to an antidepressant with lower constipation risk may be necessary if symptoms persist 1

Monitoring closely for all side effects, especially during the first 1-2 weeks, is crucial 1
Follow-up within 1-2 weeks of starting therapy to assess side effects and modify treatment if necessary 1
Failure to adjust treatment after 6-8 weeks if response is inadequate can lead to poor outcomes 1